Manifaxine (GW 320659) is a highly selective neuronal norepinephrine and dopamine re-uptake inhibitor. It has been in phase II clinical trials by GlaxoSmithKline for the treatment of attention deficit hyperactivity disorder and obesity. Manifaxine development has been discontinued.

Enestebol is an anabolic steroid.

Metribolone, also known as methyltrienolone, an anabolic agent, binds to the androgen receptor and was studied for the treatment of advanced breast cancer. However, because of the liver toxicity, further development of this drug was discontinued. Now, this compound is used for research purpose as synthetic androgen.

Fluazuron (N-[[4-chloro-3-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]carbamoyl]-2,6-difluorobenzamide, trade name Acatak) is an insect growth regulator belonging to the class of benzoyl phenyl urea derivatives, a class of chitin synthesis inhibitors. Fluazuron specifically interferes with chitin formation in ticks during engorgement, molt, and hatching. The substance is intended for tick control in beef cattle applied topically as a pour-on for use at single dose levels of 1.5 and 2.5 mg/kg BW with a possible additional treatment after 3 to 6 months.

Imuracetam is a drug of the racetam family patented by Belgian pharmaceutical company UCB S. A. for enhancement of memory and prevention of damage due to hypoxia.

FETOXYLATE, a phenoxyethyl ester of diphenoxylate, is an opioid receptor agonist. It is used as antidiarrheal.

Tilsuprost is an iminoprostacyclin derivative patented by Hoechst A.-G. as stable prostacyclin analog useful cytoprotective agent. In preclinical models, Tilsuprost given just before induction of pancreatitis partly prevented the impairment of mitochondrial oxidative and phosphorylative functions, however, these positive effects were limited in acute pancreatitis preceded by acute ethanol intake.

Albutoin has been shown to have an anticonvulsant activity against clonic and tonic experimental seizures in mice and rats, particularly those induced by pentylenetetrazol. The first report, in 1959, of the clinical use of albutoin indicated that the drug was more effective in tonic-clonic seizures than in absence seizures. Albutoin was marketed in Europe as CO-ORD and Euprax by Baxter Laboratories. Albutoin was not approved by the United States Food and Drug Administration.

Lesopitron is a non-benzodiazepine anxiolytic with pre- and post-synaptic 5-HT1A agonist activity. Its structure is similar to that of buspirone. Lesopitron has negligible effects on alpha-adrenergic and dopaminergic receptors [162653], and was more potent than structurally-related 5-HT1A agonists in rat social interaction and marmoset anxiety models. It also countered benzodiazepine withdrawal-induced anxiety in rodents. The acute toxicity of lesopitron is low and it does not potentiate the effects of alcohol or barbiturates. Long-term usage led to reductions in plasma glucose, triglycerides, phospholipids and cholesterol. The most common adverse events associated with lesopitron were somnolence, headache, pharyngitis, and dyspepsia.